AEGiS-11IAC: Immunogenicity of a live recombinant canarypox virus expressing gp120tm-MN/gag/protease-LAI (vCP205) boosted with a p24e/v3-MN peptide (CLTB-36) in HIV-negative volunteers (anrs vac 03).

11th International AIDS Conference

Vancouver, British Columbia — July 7-12, 1996

Immunogenicity of a live recombinant canarypox virus expressing gp120tm-MN/gag/protease-LAI (vCP205) boosted with a p24e/v3-MN peptide (CLTB-36) in HIV-negative volunteers (anrs vac 03).

Int Conf AIDS 1996 Jul 7-12; 11:7 (abstract no. Mo.A.155)
Salmon D, Excler JL, Finkielsztejn L, Chapuis L, Heshmati F, Gluckman JC, Autran B, Meignier B, Klein M, Sicard D; Hopital Cochin, Medecine Interne, Paris, France. Fax: 33-1-43 26 88 92. E-mail: Laufink@pratique.fr.

30 healthy volunteers at low risk for HIV infection were immunized with vCP205 at 105.8 TCID50 and or CLTB-36 240 micrograms, and randomly assigned.

RESULTS: At month 7 of lymphoproliferative response (LPR) and cytotoxic T lymphocyte activity (CTL) were as follows: (table: see text) Neutralizing antibodies to HIV-1 MN were detected in 5/15 volunteers of groups C and D one month after the 4th injection, but none of the sera could neutralize an HIV-1 primary isolate. In conclusions: these preliminary results suggest that: CLTB-36 is poorly immunogenic; p24E is not an immunodominant T helper epitope in this population; 4 x vCP205 are able to induce both humoral and cellular responses; CTL activity although low, is broadened against env, gag and pol, CD8+ / CD4+ mediated and HLA-I restricted in some subjects. Booster injections did not enhance responses. Priming with higher doses of vCP205 and boosting with subunits such as gp120, p24 or pseudovirions might be worth testing in humans.

Keywords: AEGIS, HIV-1, Antineoplastic Combined Chemotherapy Protocols, T-Lymphocytes, Cytotoxic, HIV Infections, Peptides, HIV Protease, Endopeptidases, CAV protocol, VAC protocol, Human, ICA11

960707
MoA155